Enzo Clinical Lab and DiaSorin Collaborate
News Oct 18, 2013
“Our agreement with DiaSorin has multiple benefits that, in addition to providing additional cutting edge diagnostic technology to physicians and their patients from a global leader in the in vitro diagnostics field, also reflects an acknowledgement of the excellent and expanding capabilities of our Lab, a center of excellence, in evolving medical science,” said Barry Weiner, Enzo President.
As part of the agreement, Enzo Clinical Labs has added two new DiaSorin LIAISON® XL Analyzers, a new high throughput, chemiluminescent, random access analyzer that provides a menu of over 30 assays. The system requires no daily maintenance with most tests and can manage up to 25 different assays on board.
“We are excited to collaborate with Enzo to provide high quality automated testing solutions to best serve their clients with an opportunity for growth and improved patient care,” said John Eskdale, DiaSorin President. “The LIAISON® XL, with its expanded menu, will offer Enzo a competitive advantage in the areas of specialty testing which include infectious disease, growth, hypertension, and bone & mineral.”
Enzo Labs initially will offer a number of DiaSorin LIAISON® XL tests to its customers, including the LIAISON® 25 OH Vitamin D TOTAL assay, which measures both 25-OH D2 and 25-OH D3 metabolites to accurately assess Vitamin D sufficiency. Enzo will also offer DiaSorin’s CMV IgM and Borrelia burgdorferi assays, and is currently evaluating the company’s new LIAISON® Direct Renin and Aldosterone assays. These tests are the only fully automated, FDA cleared chemiluminescent assays available for the diagnosis and treatment of certain types of hypertension and primary aldosteronism.
Enzo and DiaSorin will continue to evaluate the entire line of LIAISON® assays to assure Enzo’s clientele of the availability of the most advanced and high quality immunoassays.
Comments | 0 ADD COMMENT
PSA Microfluidic Assay Clinical Validation Initiated
News Jan 11, 2017